Browsing by Author "Singh U."
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Bayesian estimation of the number of species from Poisson-Lindley stochastic abundance model using non-informative priors(Springer Science and Business Media Deutschland GmbH, 2024) Pathak A.; Kumar M.; Singh S.K.; Singh U.; Kumar S.In this article, we propose a Poisson-Lindley distribution as a stochastic abundance model in which the sample is according to the independent Poisson process. Jeffery�s and Bernardo�s reference priors have been obtaining and proposed the Bayes estimators of the number of species for this model. The proposed Bayes estimators have been compared with the corresponding profile and conditional maximum likelihood estimators for their square root of the risks under squared error loss function (SELF). Jeffery�s and Bernardo�s reference priors have been considered and compared with the Bayesian approach based on biological data. � The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.Item Bayesian inferences and prediction of exponentiated exponential distribution based on multiple interval censored data(Springer Science and Business Media Deutschland GmbH, 2024) Agnihotri S.; Singh S.K.; Singh U.This article carefully defines a multiple interval censoring plan, and its scope of application in the Bayesian setup is demonstrated. The Bayes estimators of shape and scale parameters of the exponentiated exponential distribution are obtained under symmetric and asymmetric loss functions. Additionally, the credible intervals for both parameters are obtained. The performances of Bayes estimators and credible intervals are investigated through the appropriate Monte Carlo method. Furthermore, the authors also considered the prediction of future samples as well as the prediction interval. Lastly, a real-world example is presented in order to illustrate the effectiveness of the proposed methods. � The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.Item E-Bayesian inference for xgamma distribution under progressive type II censoring with binomial removals and their applications(Taylor and Francis Ltd., 2024) Pathak A.; Kumar M.; Singh S.K.; Singh U.; Tiwari M.K.; Kumar S.In this article, we propose E-Bayes estimators of the parameter of xgamma distribution under squared error loss function, general entropy loss function, and linear exponential loss function for progressive type II censored data with binomial removals. The proposed estimators, maximum likelihood estimator, and corresponding Bayes estimators are compared in terms of their risks based on simulated samples from xgamma distribution. The proposed methodology is illustrated on two real data sets of bile duct cancer data and the endurance of deep-groove ball bearings data. � 2023 Informa UK Limited, trading as Taylor & Francis Group.Item Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries(Elsevier Inc., 2024) Kaliki S.; Vempuluru V.S.; Mohamed A.; Al-Jadiry M.F.; Bowman R.; Chawla B.; Hamid S.A.; Ji X.; Kapelushnik N.; Kebudi R.; Sthapit P.R.; Rojanaporn D.; Sitorus R.S.; Yousef Y.A.; Fabian I.D.; Abdulqader R.A.; Aggarwal P.; Ahmad A.; Akib M.N.R.; Al Mesfer S.A.; Al Ani M.H.; Al-Badri S.A.F.; Angeles Alcasabas A.P.; Al-Dahmash S.A.; Al-Haddad C.; Yahya Al-Hussaini H.H.; Al-Jumaily U.; Alkatan H.M.; Razzaq Mahmood Al-Mafrachi A.A.; Samad Majeed Al-Shaheen A.A.; Al-Shammary E.H.; Amiruddin P.O.; Armytasari I.; Astbury N.J.; Atalay H.T.; Ataseven E.; Atchaneeyasakul L.-O.; Balayeva R.; Bascaran C.; Begimkulova A.S.; Bhaduri A.; Bhat S.; Bhattacharyya A.; Blum S.; Buaboonnam J.; Burton M.J.; Caspi S.; Chaudhry S.; Chen W.; Chuluunbat T.; Dangboon W.; Das A.; Das P.; Das S.; Du Y.; Dudeja G.; Eka Sutyawan I.W.; Fadoo Z.; Faranoush M.; Foster A.; Frenkel S.; Ghassemi F.; Gomel N.; Gunasekera D.S.; G�nd�z A.K.; Gupta H.; Gupta S.; Gupta V.; Hamzah N.; Hasanreisoglu M.; Hassan S.; Haydar H.A.; Hongeng S.; Hussein Al-Janabi A.N.; Islamov Z.; Janjua T.A.; Jeeva I.; Jo D.H.; Kantar M.; Keomisy J.; Khan Z.J.; Khaqan H.A.; Khetan V.; Khodabande A.; Kim J.H.; Kiratli H.; Ko� I.; Kulvichit K.; Kuntorini M.W.; Li C.; Li K.; Limbu B.; Liu C.; Lutfi D.; Mahajan A.; Maitra P.; Makimbetov E.K.; Maktabi A.M.Y.; Manzhuova L.; Masud S.; Mehrvar A.; Menon V.; John V Mercado G.; Chandra Mishra D.K.; Mohammad M.T.; Mudaliar S.S.; Mushtaq A.; Nair A.G.; Natarajan S.; Nency Y.M.; Neroev V.; Nuruddin M.; Pagarra H.; Palanivelu M.S.; Papyan R.; Pe'er J.; Polyakov V.; Qadir A.O.; Qayyum S.; Qian J.; Quah B.; Rahman A.; Rajkarnikar P.; Ramanjulu R.; Rashid R.; Roy S.R.; Saab R.H.; Saakyan S.; Sabhan A.H.; Saiju R.; Sayalith P.; Sedaghat A.; Seth R.; Shakoor S.A.; Sharma M.K.; Siddiqui S.N.; Singh U.; Singha P.; Soebagjo H.D.; Sultana S.; Sun X.; Supriyadi E.; Surukrattanaskul S.; Suzuki S.; Tan D.; Tang J.; Tashvighi M.; Teh K.H.; Tehuteru E.S.; Thawaba A.D.M.; Toledano H.; Le Trang D.; Tripathy D.; Tuncer S.; Unal E.; Ushakova T.L.; Usmanov R.; Verma N.; Victor A.A.; Vishnevskia-Dai V.; Wang Y.-Z.; Wangtiraumnuay N.; Riono W.P.; Wiwatwongwana A.; Wiwatwongwana D.; Wong E.S.; Wongwai P.; Wu S.-Q.; Xiang D.; Xiao Y.; Xu B.; Xue K.; Yam J.C.; Yang H.; Yaqub M.A.; Yarovaya V.A.; Yarovoy A.A.; Ye H.; Yuliawati P.; Zhang Y.; Zia N.; Zondervan M.Purpose: To describe the clinical presentation and treatment outcomes of children who received a diagnosis of retinoblastoma in 2017 throughout Asia. Design: Multinational, prospective study including treatment-na�ve patients in Asia who received a diagnosis of retinoblastoma in 2017 and were followed up thereafter. Participants: A total of 2112 patients (2797 eyes) from 96 retinoblastoma treatment centers in 33 Asian countries. Interventions: Chemotherapy, radiotherapy, enucleation, and orbital exenteration. Main Outcome Measures: Enucleation and death. Results: Within the cohort, 1021 patients (48%) were from South Asia (SA), 503 patients (24%) were from East Asia (EA), 310 patients (15%) were from Southeast Asia (SEA), 218 patients (10%) were from West Asia (WA), and 60 patients (3%) were from Central Asia (CA). Mean age at presentation was 27 months (median, 23 months; range, < 1�261 months). The cohort included 1195 male patients (57%) and 917 female patients (43%). The most common presenting symptoms were leukocoria (72%) and strabismus (13%). Using the American Joint Committee on Cancer Staging Manual, Eighth Edition, classification, tumors were staged as cT1 (n = 441 [16%]), cT2 (n = 951 [34%]), cT3 (n = 1136 [41%]), cT4 (n = 267 [10%]), N1 (n = 48 [2%]), and M1 (n = 129 [6%]) at presentation. Retinoblastoma was treated with intravenous chemotherapy in 1450 eyes (52%) and 857 eyes (31%) underwent primary enucleation. Three-year Kaplan-Meier estimates for enucleation and death were 33% and 13% for CA, 18% and 4% for EA, 27% and 15% for SA, 32% and 22% for SEA, and 20% and 11% for WA (P < 0.0001 and P < 0.0001), respectively. Conclusions: At the conclusion of this study, significant heterogeneity was found in treatment outcomes of retinoblastoma among the regions of Asia. East Asia displayed better outcomes with higher rates of globe and life salvage, whereas Southeast Asia showed poorer outcomes compared with the rest of Asia. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. � 2023 American Academy of Ophthalmology